Evaluation and Chemotherapy of Residual Disease in Acute Leukemia

  • R. Zittoun
  • J. P. Marie
Part of the Developments in Oncology book series (DION, volume 19)

Abstract

During the last fifteen years major progress has been accomplished in the induction treatment of acute leukemia in adults, with about 70 % complete remission (CR), achieved in acute myelogenous leukemia (AML) and in acute lymphoblastic leukemia (ALL), except in old and poor prognostic patients — secondary leukemias, blast crisis —. However in most center the number of long term survivors is still lower than 5 % (30). In our department, only 2 % of the 806 patients referred during the 11 last years are alive in their first CR for more than 4 years. The risk of relapse after a prolonged CR is low: we have observed two such AML patients who relapsed after 5 and 8 years of CR, but this occurs unfreguently — 2.8 % of cases in a large multicentric study (30) —. Extensive histologic examinations have shown a high frequency of occult foci of leukemic cells in various tissues when such surveys were made shortly after the establishment of CR (20), whereas similar studies in ALL patients in continuous CR for three or more years revealed only few positive testicular biopsies (17). One can hypothesize consequently that the leukemic cell burden in most patients in short term CR is relatively high, not far under the 1010 cells corresponding to the limit between overt disease and CR. Cytogenetic studies have shown that most relapses — even after bone marrow allogenic transplant — originate from the initial clone, taking into account clonal evolution and/or subclones expansion. Evaluation and treatment of the residual disease, once a CR is obtained, is therefore actually the major task in the treatment of acute leukemia.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.-
    Arlin ZA, Fried J, Clarkson BD. Therapeutic role of cell kinetics in acute leukeamia. Clinics in Haemat. 1978, 7: 339–362.CrossRefGoogle Scholar
  2. 2.-
    Arlin ZA, Mertelsmann R., Kempin S, Gee T, Clarkson BD. Is further intensification of treatment warranted in acute non lymphoblastic leukemia? Cancer Treat. Rep. 1982, 67: 202 (see replies from R J Mayer et al and H. Preisler).Google Scholar
  3. 3.-
    Baker MA, Falk JA, Carter WH, Taur RN and the Toronto Leukemia Study Group. Early diagnosis of relapse in acute myeloblastic leukemia. Serologic detection of leukemia-associated antigens in human marrow. New. Eng. J. Med. 1979, 301: 1353–1357.PubMedCrossRefGoogle Scholar
  4. 4.-
    Bhalla K, Stillman I, Grant S. Selective eradication of Ara-C-resistant leukemic cells utilizing combinations of thymidine and deoxycytidine Blood 1982, 60, suppl. 1: 152 a.Google Scholar
  5. 5.-
    Bradstock KF, Ganossy G, Tidman N et al. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukemia Leuk. Res. 1981, 5: 301–309.PubMedCrossRefGoogle Scholar
  6. 6.-
    Dahl GV, Kalwinsky DK, Murphy S et al. Cytokinetically based induction chemotherapy and splenectomy for childhood acute non lymphocytic leukemia. Blood 1982, 60: 856–863.PubMedGoogle Scholar
  7. 7.-
    Gale RP, Foon KA, Cline MJ, Zighelboim J and the UCLA Acute Leukemia Study Group Intensive chemotherapy for acute myelogenous leukemia. Ann. Int. Med. 1981, 94: 753–757.PubMedCrossRefGoogle Scholar
  8. 8.-
    Greaves M, Paxton A, Janossy G, Pain C, Johnson S, Lister TA Acute lymphoblastic leukaemia associated antigen. III Alterations in expression during treatment and in relapse Leuk. Res. 1980, 4: 1–14.PubMedCrossRefGoogle Scholar
  9. 9.-
    Hagenbeek A, Martens ACM. Kinetics of minimal residual disease in a rat model for human acute myelocytic leukemia in Experimental Hematology Today. SO Baum, G.D. Ledney and DW van Bekkum Editors. S. Karger. Basel 1980, p 215–221.Google Scholar
  10. 10.-
    Hande KR, Stein RS, Mc Donough DA, Greco FA Effects of high-dose cytarabine Clin. Pharmacol. Therap. 1982, 31: 669–674CrossRefGoogle Scholar
  11. 11.-
    Hervé P. Personnal communication.Google Scholar
  12. 12.-
    Hines JD, Oken MM, Mazza J, Keller A, Click J High dose cytosine arabinoside (Ara-C) and m-AMSA in refractory acute non-lymphoblastic leukemia. Blood 1981, 58, Suppl. 1: 142 a.Google Scholar
  13. 13.-
    Karanes C, Wolff SN, Herzig GP High dose cytosine arabinoside in the treatment of patients with refractory acute non-lymphocytic leukemia Blood 1979, 54 supp 1: 191 a.Google Scholar
  14. 14.-
    Keating MJ, Smith TL, Cehan LA et al. Factors related to the length of complete remission in adult acute leukemia. Cancer 1980, 45: 2017–2029.PubMedCrossRefGoogle Scholar
  15. 15.-
    Legha SS, Keating MJ, Mc Credie KB, Bodey GP, Freireich EJ Evaluation of AMSA in previously treated patients with acute leukemia: Reseults of therapy in 109 adults Blood 1982, 60: 484–490.PubMedGoogle Scholar
  16. 16.-
    Lister TA, Rohatiner AZS. The treatment of acute myelogenous leukemia in adults. Seminars Hemat. 1982, 19: 172–192.Google Scholar
  17. 17.-
    Mahoney D, Gonzales ET, Ferry GD et al. Childhood acute leukemia: a search for occult extramedullary disease prior to discontinuation of chemotherapy. Cancer 1981, 48: 1964–1966.PubMedCrossRefGoogle Scholar
  18. 18.-
    Marie GP, Zittoun R, Thevenin D, Mathieu M, Viguie F. In-vitro culture of clonogenic leukaemic cells in acute myeloid leukaemia: growth pattern and drug sensitivity Br. J. Haemat. (to be published).Google Scholar
  19. 19.-
    Mathe G., de Gager R, Hulhoven R et al. L’aclacinomycin A dans les leucémies aigues et les lymphomes non-hodgkiniens leucémiques. Nouv. Presse Med. 1982, 11: 25–28.PubMedGoogle Scholar
  20. 20.-
    Mathe G, Schwarzenberg L, Mery AM et al. Extensive histological and cytological survey of patients with acute leukaemia in “complete remission”. Br. Med. J. 1966, 1: 640–642.PubMedCrossRefGoogle Scholar
  21. 21.-
    Mayer RG, Weinstein HD, Coral FS, Rosenthal DS, Frei E III The role of intensive post-induction chemotherapy in the management of patients with acute myelogenous leukemia Cancer Treat. Rep. 1982, 66: 1455–1462.PubMedGoogle Scholar
  22. 22.-
    Peterson BA, Bloomfield CD Re-Induction of complete remissions in adults with acute non-lymphocytic leukemia. Leuk. Res. 1981, 5: 81–88.PubMedCrossRefGoogle Scholar
  23. 23.-
    Preisler HD Therapy for patients with acute myelocytic leukemia who enter remission: bone marrow transplantation or chemotherapy ? Cancer Treat. Rep. 1982, 66: 1467–1473.PubMedGoogle Scholar
  24. 24.-
    Schabel FM Jr, Skipper HE, Trader MW et al. Drug control of Ara-C resistant tumor cells. Med. Pediatr. Oncol. 1982, Suppl. 1: 125–148.CrossRefGoogle Scholar
  25. 25.-
    Schmid FA, Hutchison DG, Otter GM, Stock CC Development of resistance to combinations of six antimetabolites in mice with L1210 leukemia. Cancer Treat. Rep. 1976, 60: 23–27.PubMedGoogle Scholar
  26. 26.-
    Streifel GA, Howell SB Synergistic interaction between 1-β-D-arabinofuranosulcytosine, thymidine, and hydroxyurea against human B cells and 1eukemia blasts in vitro. Proc. Natl. Acad. Sci. USA 1981, 78: 5132–5136.PubMedCrossRefGoogle Scholar
  27. 27.-
    Stryckmans P, Debusscher L, Ronge-collard E, Socquet M, Zittoun R The labelling index of marrow myeloblasts: a predictive test for relapse of acute non-lymphoblastic leukemia Leuk. Res. 1980, 4: 79–87.PubMedCrossRefGoogle Scholar
  28. 28.-
    Van Echo DA, Markus S, Wiernik PH A phase III trial of Arabinosyl-cytosine and thymidine (Ara-C + TdR) in adult relapsed acute leukemia (AL) Proceed 17th. Ann. Meet. Amer. Soc. Clin. Oncol. 1981, 22: 483.Google Scholar
  29. 29.-
    Vogler WR, Miller DS, Keller JJW (Writing Committe for the Southeastern Cancer Study Group). 5-Azacytidine (NSC 102816). A new drug for the treatment of Myeloblastic Leukemia. Blood 1976, 48: 331–337.PubMedGoogle Scholar
  30. 30.-
    Whittaker JA, Reizenstein P, Callender ST et al. Long survival in acute myelogenous leukaemia: an international collaborative study. Br. Med. J. 1981, 282: 692–695.CrossRefGoogle Scholar
  31. 31.-
    Willemze R, Zwaan FE, Colpin C, Keuning JJ High dose cytosine arabinoside in the management of refractory acute leukaemia. Scand. J. Haematol. 1982, 29: 141–146.PubMedCrossRefGoogle Scholar
  32. 32.-
    Wolff SN, Marion J, Stein R, Flexner JM, Phillips GL, Herzig GP Therapy of acute non-lymphoblastic leukemia (ANLL) in first remission: Brief intensive consolidation with high-dose Ara-C (HDARAC). Blood 1982, 60 supplt. 1: 159 a.Google Scholar
  33. 33.-
    Yap B.S., Mc Credie KB, Keating MJ, Bodey GP, Freireich EJ Phase I–II study of 3-deazauridine in adults with acute leukemia. Cancer Treat. Rep. 1981, 65: 521–524.PubMedGoogle Scholar
  34. 34.
    Zittoun R, Cadiou M, Bayle C, Suciu S, Solbu G, Hayat M, and the EORTC Leukemia and Hematosarcoma Group. Prognostic value of cytological parameters in acute myelogenous leukemia. Cancer (to be published).Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1984

Authors and Affiliations

  • R. Zittoun
  • J. P. Marie

There are no affiliations available

Personalised recommendations